Rankings / Metabolic Health

Icosapent ethyl (Vascepa)

Metabolic Health · Purified EPA ester

Tier A-

Reviewed by Read Off Label · Last reviewed · How we grade

omega-3af-dose-responseprescription
7.6 / 10
Tier A-
Ev 8 Bn 8 Sf 7

Bottom line

Read Off Label grades Icosapent ethyl (Vascepa) as A- (7.6/10) based on strong evidence, strong benefit magnitude, and a low-med-risk safety profile.

REDUCE-IT (2018) remains the pivotal Western trial.

Studied, labeled, or reported-use context: 4 g/day PO (2 g twice daily with food); RESPECT-EPA-style protocols use 1. — Rx; not individualized guidance.

What the evidence says

REDUCE-IT (2018) remains the pivotal Western trial. STRENGTH (mixed EPA+DHA carboxylic acid 2020) was negative — prompting debate whether (a) pure EPA is specifically beneficial vs. (b) REDUCE-IT's mineral oil placebo artifactually inflated effect by raising LDL/ApoB/CRP in the control arm. **RESPECT-EPA** (Japan 2024, n=2460, 1.8 g/day icosapent in CAD with low EPA:AA ratio) helps adjudicate: primary endpoint just missed (HR 0.79, p=0.055) but the secondary coronary endpoint reached significance (HR 0.73) — and crucially RESPECT-EPA used a non-mineral-oil control, weakening the placebo-confound objection. RESPECT-EPA also confirmed the AF dose signal (3.1% EPA vs 1.6% control, p=0.017) at 1.8 g — lower than the 4 g REDUCE-IT dose. 2024 Frontiers Nutrition review proposes analytical approaches to reconcile REDUCE-IT/STRENGTH discrepancies. Current guidelines support use in elevated-TG patients on statins; the RESPECT-EPA data support a lower-dose option in EPA:AA-deficient CAD patients but with explicit AF monitoring.

Mechanism

Highly purified EPA ethyl ester; lowers triglycerides; incorporates into membrane phospholipids; generates resolvins; plaque stabilization; restores EPA:AA ratio (a Japanese-specific clinical biomarker)

Studied, labeled, or reported dose & route

4 g/day PO (2 g twice daily with food); RESPECT-EPA-style protocols use 1.8 g/day in EPA:AA-deficient patients

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Icosapent ethyl (Vascepa)'s effects?
Read Off Label rates the evidence for Icosapent ethyl (Vascepa) as Strong and the benefit magnitude as strong, producing an overall grade of A- (7.6/10). REDUCE-IT (2018) remains the pivotal Western trial.
What safety findings are reported for Icosapent ethyl (Vascepa)?
Icosapent ethyl (Vascepa) has a low-med risk profile in the database. Low-Med (dose-dependent AF signal — RESPECT-EPA confirmed new-onset AF 3.1% vs 1.6% p=0.017 at 1.8 g/day; minor bleeding; burping) Legal status: Rx (generic available since 2022).
What doses or routes are reported for Icosapent ethyl (Vascepa)?
4 g/day PO (2 g twice daily with food); RESPECT-EPA-style protocols use 1.8 g/day in EPA:AA-deficient patients This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Icosapent ethyl (Vascepa) work?
Highly purified EPA ethyl ester; lowers triglycerides; incorporates into membrane phospholipids; generates resolvins; plaque stabilization; restores EPA:AA ratio (a Japanese-specific clinical biomarker)

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.